Cumulative incidence of NRM of recipients of allogeneic HCT with HR TA-TMA: eculizumab (n = 19) vs supportive care (n = 36) (A), distribution of inpatient cost per day (B), total cost (C), and subcategories of cost in recipients of allogeneic HCT with HR TA-TMA (n = 55) based on treatment approach (D). (A) There was no significant difference in the rate of NRM for allogeneic HCT recipients who were stratified as having HR TA-TMA and treated with eculizumab vs those who received supportive care only (P = .48). One-year NRM of patients with TA-TMA diagnosis treated with eculizumab vs supportive care only was 47.4% ± 11.9% and 33.6% ± 8.0%, respectively. (B) Eculizumab (n = 19) vs supportive care (n = 36): cost per day from day 15 to day 365 after HCT (P < .001). (C) Eculizumab (n = 19) vs supportive care (n = 36): total cost (P = .001). (D) Total costs broken down according to cost subcategory in the allogeneic HCT HR TA-TMA cohort, depicted as cost percentage (%) among those treated with eculizumab and supportive care.